Who owns SILENCE THERAPEUTICS PLC?
- Ticker: SLN
- CUSIP Number: 82686q101
Tip: Access positions for across all investors
Analyze quarterly positions in Silence Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Silence Therapeutics stock
Who bought or sold SILENCE THERAPEUTICS PLC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Artal Group | 2.8M | $60M | -7% | Mar 2024 |
|
| Lombard Odier Asset Management | 2.4M | $42M | -41% | Mar 2024 |
|
| Lombard Odier Asset Management | 2.2M | $48M | -35% | Mar 2024 |
|
| Redmile Group | 2.0M | $44M | 100% | Mar 2024 |
|
| Logos Global Management | 1.5M | $31M | 269% | Mar 2024 |
|
| Frazier Life Sciences Management | 1.1M | $25M | 30% | Mar 2024 |
|
| Vivo Capital | 1.1M | $24M | 117% | Mar 2024 |
|
| Nextech Invest | 952k | $21M | 100% | Mar 2024 |
|
| Henderson Group | 626k | $14M | 100% | Mar 2024 |
|
| Cormorant Asset Management | 625k | $14M | 100% | Mar 2024 |
|
| Adage Capital Partners GP | 600k | $13M | 100% | Mar 2024 |
|
| Aquilo Capital Management | 574k | $12M | -45% | Mar 2024 |
|
| Lynx1 Capital Management | 527k | $11M | 123% | Mar 2024 |
|
| 5AM Venture Management | 476k | $10M | 100% | Mar 2024 |
|
| Millennium Management | 409k | $8.8M | 100% | Mar 2024 |
|
| Duquesne Family Office | 387k | $8.4M | 100% | Mar 2024 |
|
| Mangrove Partners | 385k | $8.3M | 100% | Mar 2024 |
|
| M28 Capital Management | 364k | $6.3M | 0% | Dec 2023 |
|
| Octagon Capital Advisors | 315k | $6.8M | 100% | Mar 2024 |
|
| Hudson Bay Capital Management | 277k | $6.0M | 100% | Mar 2024 |
|
| Parkman Healthcare Partners | 245k | $5.3M | 27% | Mar 2024 |
|
| Morgan Stanley | 243k | $5.2M | 356% | Mar 2024 |
|
| Woodline Partners | 238k | $5.1M | 43% | Mar 2024 |
|
| Nantahala Capital Management | 200k | $4.3M | 100% | Mar 2024 |
|
| Hsbc Holdings | 178k | $3.1M | 0% | Dec 2023 |
|
| Marshall Wace | 139k | $3.0M | 100% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 133k | $2.9M | 170% | Mar 2024 |
|
| Boothbay Fund Management | 127k | $2.7M | 100% | Mar 2024 |
|
| Two Sigma Investments | 107k | $2.3M | 100% | Mar 2024 |
|
| Cantor Fitzgerald, L. P. | 104k | $2.2M | -29% | Mar 2024 |
|
| Walleye Trading Advisors | 92k | $2.0M | 100% | Mar 2024 |
|
| Two Sigma Advisers | 77k | $1.7M | 100% | Mar 2024 |
|
| UBS O'Connor | 72k | $1.6M | 100% | Mar 2024 |
|
| UBS Group | 72k | $1.6M | 3% | Mar 2024 |
|
| Citigroup | 58k | $1.3M | 0% | Mar 2024 |
|
| Artia Global Partners | 53k | $1.1M | 100% | Mar 2024 |
|
| Citadel Advisors | 43k | $922k | 96% | Mar 2024 |
|
| ADAR1 Capital Management | 40k | $866k | 21000% | Mar 2024 |
|
| Cubist Systematic Strategies | 36k | $784k | 100% | Mar 2024 |
|
| William Blair $ Company | 25k | $549k | 0% | Mar 2024 |
|
| Geode Capital Management | 22k | $484k | 5% | Mar 2024 |
|
| Goldman Sachs Group | 22k | $470k | 100% | Mar 2024 |
|
| Rathbones Brothers | 20k | $430k | 100% | Mar 2024 |
|
| Shay Capital | 15k | $327k | 100% | Mar 2024 |
|
| Bank of America Corporation | 12k | $259k | 1014% | Mar 2024 |
|
| NEOS Investment Management | 12k | $252k | 100% | Mar 2024 |
|
| Advisor Group Holdings | 11k | $236k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 9.6k | $208k | 100% | Mar 2024 |
|
| Point72 Asset Management | 8.2k | $177k | 100% | Mar 2024 |
|
| SG Americas Securities | 7.0k | $151k | 11% | Mar 2024 |
|
| Barclays | 5.6k | $120k | 100% | Mar 2024 |
|
| Qube Research & Technologies | 3.9k | $85k | 2115% | Mar 2024 |
|
| Lazard Asset Management | 2.3k | $0 | 5% | Dec 2023 |
|
| Advisors Preferred | 1.1k | $24k | 100% | Mar 2024 |
|
| GAMMA Investing | 876.00 | $19k | -5% | Mar 2024 |
|
| Steward Partners Investment Advisory | 100.00 | $2.2k | 0% | Mar 2024 |
|
| Rhumbline Advisers | 15.00 | $324.000000 | 200% | Mar 2024 |
|
Who sold out of Silence Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| BVF | Dec 2023 | 1.5M | $26M |